Mostrar el registro sencillo del ítem

Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia

dc.contributor.advisorGalindo Quintero, Jaime
dc.contributor.advisorMartínez Cajas, Jorge
dc.contributor.authorGalindo Orrego, Pablo
dc.date.accessioned2012-11-14T19:17:11Z
dc.date.available2012-11-14T19:17:11Z
dc.date.created2012
dc.date.issued2012-11-14
dc.identifier.citationWHO. Status of the Global HIV epidemic at http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf.
dc.identifier.citationMurphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17- 26.
dc.identifier.citationPalella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
dc.identifier.citationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 10, 2011. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC).
dc.identifier.citationMasquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection with zidovudine-resistant HIV. N Engl J Med 329(15):1123–1124 (1993).
dc.identifier.citationDavid A.M.C. van de Vijver, Annemarie M.J. Wensing, Charles A.B. Boucher, Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherland. The Epidemiology of Transmission of Drug Resistant HIV-1, 2008.
dc.identifier.citationLittle SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394.
dc.identifier.citationWheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-1212.
dc.identifier.citationWensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed patients with HIV from 17 european countries shows that 10% of the patients carry primary drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1.
dc.identifier.citationSimon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.
dc.identifier.citationToni T, Masquelier B, Bonard D et al. Primary HIV-1 drug resista
dc.identifier.citationPetroni A, Deluchi G, Pryluka D et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42(4):506–510 (2006).
dc.identifier.citationTruong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006).
dc.identifier.citationRodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116(1–2):201-207 (2006).
dc.identifier.citationBrindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17(7):1063– 1069 (2003).
dc.identifier.citationLama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006).
dc.identifier.citationFrentz, Dineke, Boucher, Charles A. B. and van de Vijver, David A. M. C. (2012), "Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World", AIDS Reviews
dc.identifier.citationTruong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006).
dc.identifier.citationLama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006).
dc.identifier.citationDiazGranados, C. Mantilla, W.Lenis, W. n Antiretroviral drug resistance in HIV-infected patients in Colombia. International Journal of Infectious Diseases 2010;14:e298–e303.
dc.identifier.citationKuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870.
dc.identifier.citationBangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72
dc.identifier.citationOette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581 (2006).
dc.identifier.citationWeinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12):2174–2180 (2004).
dc.identifier.citationNovak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40(3):468–474 (2005)
dc.identifier.citationJayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42(1):86–90 (2006).
dc.identifier.citationPoon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load
dc.identifier.citationPalella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84
dc.identifier.citationWegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30.
dc.identifier.citationBarbour, JD, Hecht, FM, Wrin, T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683.
dc.identifier.citationWeinstock, HS, Zaidi, et al. The epidemiology of antiretroviral drug resistance among drugnaive HIV-1 infected person in 10 US cities. J Infect Dis 2004; 189:2174
dc.identifier.citationTommy F. Liu and Robert W. Shafer. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. CID 2006:42 (1 June).
dc.identifier.citationAntonella Cingolania, Antinorib, Rizzoa, Murria, Ammassaria, Baldinia, Di Giambenedettoa, Caudaa and De Lucaa. Usefulness of monitoring HIV drug resistance and Adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369±379.
dc.identifier.citationGrant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181–188 (2002).
dc.identifier.citationHarzic M, Pellegrin I, Deveau C et al. Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatment. AIDS 16(5):793-796 (2002).
dc.identifier.citationHammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296(7):827–843 (2006).
dc.identifier.citationVandamme AM, Sonnerborg A, it-Khaled M et al. Updated European recommendations for theclinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848 (2004).
dc.identifier.citationSax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316- 1323.
dc.identifier.citationMartin S. Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes, Mellors, Pillay,Yeni, Jacobsen, and Richman. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. CID 2008:47 (15 July)
dc.identifier.citationRhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009 Aug 1;200(3):453-463
dc.identifier.citationJain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5(12): e15510. doi:10.1371/journal.pone.0015510.
dc.identifier.citationBennet DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009: 4(3);1-8. e4724
dc.identifier.citationVictoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. Schapiro, MD, and Douglas D. Richman, MD. Update of the Drug Resistance Mutations in HIV-1: December 2010. International AIDS Society–USA, Volume 18 Issue 5 December 2010.
dc.identifier.citationCohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy N Engl J Med. 2011; 365: 493-505.
dc.identifier.citationhttp://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verordenador.pdf
dc.identifier.citationhttp://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-Spanish-5-4.pdf
dc.identifier.citationOcfemia C B, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Infections; March 5-8, 2012; Seattle, Washington. Clinical Care Options.
dc.identifier.citationGuía de práctica clínica de VIH/SIDA. Recomendaciones basadas en la evidencia, Colombia. Asociación Colombiana de Infectología, vol. 10 - 4, 2006.
dc.identifier.citationhttp://summaries.cochrane.org/CD006495/antiretroviral-resistance-testing-in-treatment-naivehiv-infected-adults.
dc.identifier.urihttp://hdl.handle.net/10818/3952
dc.description55 Páginas.
dc.description.abstractSe realizo un estudio para determinar la frecuencias de resistencias trasmitidas del HIV in pacientes atendidos en la Corporación de Lucha contra el SIDA en Cali, Colombia. Se incluyeron pacientes con infección por VIH confirmada nunca expuestos a tratamiento antirretroviral y que tuvieran estudio genotípico de resistencia en el periodo del 2008 al 2010. Adicionalmente fueron incluidos en el análisis factores socio-demográficos y condiciones relacionadas con el VIH. 152 pacientes fueron incluidos, la frecuencia de resistencia primaria fue del 13.2%. Para NNRTI se encontró mutaciones de resistencia en 5.3%, para NRTI en 4.6% y para IP en 2.0%. La frecuencia de resistencia primaria en este estudio es más alta a la encontrada en estudios previos en Colombia y similar a la de otros países con mayor uso de antirretrovirales.es_CO
dc.language.isospaes_CO
dc.publisherUniversidad de La Sabana
dc.sourceUniversidad de La Sabana
dc.sourceIntellectum Repositorio Universidad de La Sabana
dc.subjectSida-Investigaciones-Colombiaes_CO
dc.subjectVIH-Investigaciones-Colombiaes_CO
dc.titleResistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombiaes_CO
dc.typebachelorThesis
dc.publisher.programEspecialización en Medicina Interna
dc.publisher.departmentFacultad de Medicina
dc.identifier.local157927
dc.identifier.localTE05622
dc.type.localTesis de especialización
dc.type.hasVersionpublishedVersion
dc.rights.accessRightsopenAccess
dc.creator.degreeEspecialista en Medicina Interna


Ficheros en el ítem

Thumbnail
Nombre:
Pablo Galindo Orrego.pdf
Tamaño:
491.7Kb
Formato:
PDF
Descripción:
Ver documento en PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem